

---

## Product Data Sheet

---

Product Name: Sarizotan

Cat. No.: GC64530

### Chemical Properties

Cas. No. 351862-32-3

Formula C<sub>22</sub>H<sub>21</sub>N<sub>2</sub>O

M.Wt 348.41

Solubility DMSO : 100 mg/mL (287.02 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

### Background

Sarizotan (EMD 128130) is an orally active serotonin 5-HT<sub>1A</sub> receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC<sub>50</sub> values of 6.5 nM (rat 5-HT<sub>1A</sub>), 0.1 nM (human 5-HT<sub>1A</sub>), 15.1 nM (rat D<sub>2</sub>), 17 nM (human D<sub>2</sub>), 6.8 nM (human D<sub>3</sub>) and 2.4 nM (human D<sub>4.2</sub>), respectively[1].

Sarizotan concentration-dependently inhibits the electrically-induced contractions with an IC<sub>50</sub> value of 150 nM (E<sub>max</sub> 40% at 1 mM) [1].

Sarizotan (3, 10 mg/kg, po) at the higher dose slightly decreases 5-HT in the striatum and its metabolite 5-HIAA in frontal cortex and hippocampus. Sarizotan (10 mg/kg, po) substantially increases the DA metabolites DOPAC and HVA in the striatum and frontal cortex[1]. Sarizotan represents a new approach for the treatment of extrapyramidal motor complications such as l-DOPA-induced dyskinesia in Parkinson's disease[1]. Sarizotan (10 ng and 1 µg, local administration) attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats[2].

[1]. G D Bartoszyk, et al. Sarizotan, a Serotonin 5-HT<sub>1A</sub> Receptor Agonist and Dopamine Receptor Ligand. J Neural Transm (Vienna). 2004 Feb;111(2):113-26.

[2]. C Marin, et al. Local Administration of Sarizotan Into the Subthalamic Nucleus

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

Attenuates Levodopa-Induced Dyskinesias in 6-OHDA-lesioned Rats.  
Psychopharmacology (Berl). 2009 Jun;204(2):241-50.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**